A recent report published by Infinium Global Research on cancer drugs market provides an in-depth analysis of segments and sub-segments in the global as well as regional cancer drugs market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional cancer drugs market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of the global cancer drugs market. According to the report, the global cancer drugs market is projected to grow at a CAGR of 7.2% over the forecast period of 2018-2024.
Cancer is a type of disease involving abnormal cell growth with a potential to spread or other parts of the body. A person without cancer has healthy tissues that grow by increasing the number of cells that make them up. Cells in many tissues in the body divide and grow in a controlled way and copy themselves to create new healthy cells. Whereas, in cancer, this process of cell division goes out of control. Cancer is caused due to viral infections, carcinogens, physical activities, tobacco & smoking, eating habits, ages, bacterial infections, and genetic causes. Further, blood cancer, bone cancer, genitourinary cancer, breast cancer, head & neck cancers, and lung cancer can be treated by oncology drugs.
Growing occurrence of different types of cancer such as breast cancer, lung and bronchus cancer, colon and rectum cancer, bladder cancer, and liver cancer has a positive impact on the growth of the market. People with cancer requires more than one type of treatment. Further, availability of many types of FDA approved drugs for several types of cancer, increasing concerns over high death rates due to cancer, and advancement in cancer treatment technology are some factors responsible for the growth of Cancer drugs market. Further, government aid and help from NGO that promotes cancer care/treatment and, the introduction of new drugs and therapies for cancer are also some factors boosting the demand for the same. However, on the contrary, the high cost of cancer treatments, and the threat of failure and the adverse effects of Cancer drugs therapy, mostly chemotherapy, hampers the growth of the Cancer drugs market. Furthermore, Introduction of novel Cancer drugs products to boost the demand for the Cancer drugs market.
Among the geographies, North America is likely to dominate the Cancer drugs market. As per the national cancer institute, approximately 38.4% of men and women will be diagnosed with cancer in the United States based on 2013–2015 data. Favorable health insurance policies, high disposable income, government, and other private institutes heavily invest in research and development activities are some factors responsible for the growth of Cancer drugs market in the North America region. Moreover, the presence of top players of pharmaceuticals in the U.S. region also increases the market in this region. Further, Europe is the second revenue-generating region for the Cancer drugs market. In Europe region, a majority of the multinational players have focused on the development of biologics or immunotherapeutic due to its high efficiency and target specific action.
The report on global cancer drugs market covers segments such as types and application. On the basis of types, the global cancer drugs market is categorized into breast cancer, gastrointestinal cancer, blood cancer, bladder cancer, liver cancer, lung and bronchus cancer, skin cancer, and others. On the basis of application, the global cancer drugs market is categorized into immunotherapy, targeted therapy, hormone therapy, and chemotherapy.
The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and Rest of the World. In this section, the key trends and market size for each geography are provided over the period of 2016-2024. The countries covered in the North America region include the U.S., Canada, and Mexico; while the Asia-Pacific region includes countries such as China, Japan, India, South Korea, Malaysia, and among others. Moreover, Germany, U.K., France, Spain, and Rest of Europe are the major markets included in the European region. The U.S. drives the growth in the North America region, as it is the largest market in the region. In the Asia-pacific region, rapid industrial growth in India and China offer a substantial potential for the growth in the cancer drugs market. As a result, the APAC region is projected to experience a growth at a CAGR of x.x% over the forecast period 2018-2024.
The report provides profiles of the companies in the global cancer drugs market such as Bayer AG, Eli Lilly and Company, Novartis AG, Amgen Inc., GlaxoSmithKline plc., Bristol-Myers Squibb Company, Pfizer Inc, Merck & Co., Inc., Celgene Corporation, Boehringer Ingelheim International GmbH, and Sanofi.
The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the global cancer drugs market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of cancer drugs market. Moreover, the study highlights current market trends and provides forecast from 2018-2024. We also have highlighted future trends in the cancer drugs market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players. This report will help manufacturers, suppliers, and distributors of the cancer drugs market to understand the present and future trends in this market and formulate their strategies accordingly.
Get free analyst support for the queries before and post purchasing report.
Be assured of 100% customer satisfaction about the research and get 24X7 customer support.
Infinium has achieved over 400%+ growth in its repository and revenue over the last 2 years. Yes, we are proud to say we are growing at a great pace and becoming a trusted partner among our clients.
sign up for our newsletter